December 8, 2017

BTS Research is finishing the year on a high note BTS Research is pleased to report their USDA inspection has been completed with 0 findings. Since BTS incubation in 2001, aside from minor recommendations from USDA that were addressed immediately, BTS enjoys a clean track record with all regulating agencies with no violations. See attached for official report

October 10, 2017

September 20, 2017 03:32 PM Eastern Daylight Time SAN DIEGO--(BUSINESS WIRE)--BTS Research announced today that they have appointed Ian Dean as their VP of Toxicology. Ian has over 27 years in the nonclinical contract research industry, with experience across UK, Canada, Asia and the US. In addition, Ian had various responsibilities in previous CRO’s such as Huntingdon Research Centre (now Envigo), Inveresk Research International (now Charles River), ITR, Southern Research Institute, LAB (now CiToxLab) and Primetrics – Singapore. In addition, Ian has spent 10 years as an independent regulatory consultant and was an Expert External Reviewer for Health Canada’s New...

October 31, 2016

BTS Research to participate in the AAPS Nov. 14-16th in Denver Colorado. https://www.aaps.org/annualmeeting/

April 8, 2016

BIO-QUANT ANNOUNCES THE EXPANSION OF ITS RESEARCH ANIMAL DIAGNOSTIC SERVICES TO COVER ALL NINE SPECIES. SAN DIEGO, CA, September, 2008 --Bio-Quant Inc ("Bio-Quant") the largest biotech Contract Research Organization (CRO) in San Diego, announced today the expansion of its animal diagnostic services division to cover all nine species used in research. Dr. Bassam Damaj, Chief Executive Officer of Bio-Quant, said, "Animal welfare is of great importance, and Bio-Quant is very pleased to announce the expansion of its Research Animal Diagnostic Services. Bio-Quant is the only local facility providing this high quality service to the San Diego community, and we will...

BIO-QUANT credited in TRIUS POSTER.

BIO-QUANT credited in XOMA POSTER.

Bio3 Research S.r.l. (Milano – Italy), is pleased to announce the positive preclinical studies outcome (conducted by the CRO Bio-Quant Inc. La Jolla/CA) obtained with HMGB1 in wound healing in mice and pigs (Vehicle and PDGF as control) which confirms the protein high potential in tissue remodeling. HMGB1 project has demonstrated in-vitro and in-vivo the dual ability of the protein to accelerate the wound healing process and to control the remodeling of collagen and fibroblasts. Bio3 Research has also tested in animals (rabbits) HMGB1 for its use in cartilage repair with encouraging results.

Los Angeles, CA. November 9, 2009 -- BioTox Sciences Attends the American Association of Pharmaceutical Scientist Annual Meeting and Exposition in Los Angeles, California.